Sanofi and Zealand Pharma obtained approval from the European Commision to market the drug Lyxumia, or lixisenatide, for treatment of diabetes. The prandial GLP-1 receptor agonist will be used with oral glucose-lowering treatments and/or basal insulin to control blood sugar levels.
Zealand-Sanofi diabetes drug wins go-ahead in Europe
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan